Obalon Therapeutics Inc. (OBLN)
NASDAQ: OBLN
· Real-Time Price · USD
3.05
-0.19 (-5.86%)
At close: Jun 16, 2021, 6:00 AM
Revenue by Geography
| Period Ending | Jun 30, 2021 |
|---|---|
| Europe Revenue | 590K |
| Europe Revenue Growth | n/a |
| Non Us Revenue | 29K |
| Non Us Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 5.75K | 4.06M | 1.23M | 1.29M | 2.36M | 3.89M | 3.64M | 2.49M | 4.33M | 6.2M | 6.85M | 5.84M | 7.25M | 10.01M | 9.22M | 7.81M | 5.85M | 5.94M | 4.83M | 2.41M | 1.6M | 1.38M | 1.19M | 618K |
| Selling, General, and Administrative Revenue Growth | -99.86% | +229.76% | -4.73% | -45.34% | -39.33% | +6.86% | +46.36% | -42.54% | -30.17% | -9.48% | +17.44% | -19.50% | -27.54% | +8.49% | +18.05% | +33.49% | -1.46% | +22.98% | +100.25% | +51.13% | +15.74% | +15.49% | +93.20% | n/a |
| Research and Development Revenue | 103 | 112K | 157K | 271K | 765K | 1.26M | 1.49M | 1.17M | 1.79M | 2.44M | 2.34M | 2.37M | 3.35M | 2.64M | 2.69M | 2.8M | 2.76M | 2.4M | 2.6M | 2.17M | 2.59M | 2.51M | 3.81M | 3.2M |
| Research and Development Revenue Growth | -99.91% | -28.66% | -42.07% | -64.58% | -39.14% | -15.75% | +27.09% | -34.34% | -26.69% | +4.32% | -1.27% | -29.36% | +27.02% | -1.86% | -3.90% | +1.38% | +15.00% | -7.87% | +20.10% | -16.13% | +2.95% | -34.05% | +18.99% | n/a |
| Sales and Marketing Revenue | 1.44K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |